You are here

A microRNA based prognostic service that predicts melanoma metastasis likelihood

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA183092-01
Agency Tracking Number: R43CA183092
Amount: $199,654.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
760 PARKSIDE AVE, RM 205
BROOKLYN, NY 11226-1508
United States
DUNS: 965188084
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ISABEL KURTH
 (646) 510-7755
 isabel.kurth@rgenix.com
Business Contact
 ISABEL KURTH
Phone: (646) 510-7755
Email: isabel.kurth@rgenix.com
Research Institution
 Stub
Abstract

ABSTRACT Melanoma is a highly prevalent cancer that kills patients by metastasizing and destroying distal organs. To date, there are no effective molecular prognostic services available for stratifying patients that are at high risk for metastatic relapsein the adjuvant setting. By stratifying patients into high-risk versus low-risk, therapies could be tailored to those patients that stand to benefit from treatment while sparing those patients who will not relapse and not require costly and potentially harmful therapies. Recent research identified three miRNAs (miR-1908, miR-199a5p, and miR-199a3p) that are overexpressed in metastatic melanoma cells and inhibit expression of apolipoprotein A (ApoE), a metastasis suppressor in melanoma. Cancer-cell secretedApoE prevents cellular invasion and metastatic endothelial recruitment through engaging melanoma cell LRP1 and endothelial cell LRP8 receptors, respectively. Importantly, elevated expression levels of miRNAs in primary tumor samples performs robustly in s

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government